BriaCell (BCTX) Therapeutics announces new “positive” Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment. Key highlights: 9 of 25 BriaCell patients treated since 2022 remain alive 18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations; No Bria-IMT related discontinuations reported to date; Bria-IMT regimen continues under Fast Track Designation from US FDA
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Therapeutics Completes $30 Million Public Offering
- BriaCell Raises $30 Million Through Public Offering of Units and Listed Warrants
- BriaCell Therapeutics trading resumes
- BriaCell Therapeutics trading halted, volatility trading pause
- BriaCell Reports Year-Long Complete Lung Metastasis Response in Breast Cancer Trial